R. Van Vollenhoven - Rhumatologie, University Medical Centre

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 37 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

S Banerjee, S Singhal, V Shah,R Van Vollenhoven, M Pike, E Morand, I Catlett, VP Werth,JT Merrill, N Delev, C Hobar, B Sharkey,

Lupus Science and Medicineno. Suppl 2 (2022)

引用0浏览0引用

Efficacité et tolérance du baricitinib chez des patients atteints de lupus érythémateux systémique : résultats de deux études de phase 3, en double insu, randomisées versus placebo

E.F. Morland, Y. Tanaka, R. Furie,E.M. Vital,R.F. Van Vollenhoven,K.C. Kalunian, M. Mosca, T. Dorner,D.J. Wallace, M.E. Silk, C.L. Dickson,I. De La Torre,

Revue du Rhumatisme（2022）

引用0浏览0引用

Pos0190 efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomised, double-blind, placebo-controlled, parallel-group, phase 3 studies

E. F. Morand, Y. Tanaka, R. Furie, E. Vital,R. van Vollenhoven,K. Kalunian,M. Mosca,T. Dörner, D. J. Wallace,M. Silk, C. Dickson,I. De La Torre,

Annals of the Rheumatic Diseases（2022）

引用11浏览0引用

Greater Reduction In Clasi-A Scores Achieved With Biib059 Versus Placebo Independently Of Disease Severity At Baseline

V. Werth, R. Furie,K. Kalunian,R. Van Vollenhoven, S. Navarra,F. Nyberg, J. Romero-Diaz,M. Tee,X. Huang,H. Carroll, C. Barbey, C. Musselli,

Annals of the Rheumatic Diseases（2021）

引用0浏览0引用

Effect Of Iberdomide On Cutaneous Manifestations In Systemic Lupus Erythematosus: Results Of A 24-Week, Placebo-Controlled, Phase 2 Study

V. Werth, J. Merrill, R. Furie, T. Doerner,R. Van Vollenhoven, P. Lipsky, M. Weiswasser, S. Korish, P. Schafer, M. Stern,Z. Liu,S. Tang,

Annals of the Rheumatic Diseases（2021）

引用8浏览0引用

OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT

M. F. Ugarte-Gil,J. Hanly,M. B. Urowitz, C. Gordon,S. C. Bae, J. Romero-Diaz, J. Sanchez-Guerrero, S. Bernatsky,A. E. Clarke,D. J. Wallace,D. Isenberg,A. Rahman,

Annals of the Rheumatic Diseases（2021）

引用0浏览0引用

The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study

John G. Hanly, Q Li,Li Su,Murray B. Urowitz,Juanita Romero-Diaz, C Gordon,S.-C. Bae, Bernatsky, Alexandra M. Clarke,Daniel J. Wallace,Joan T. Merrill, Da Isenberg,

ARTHRITIS & RHEUMATOLOGY（2015）

引用23浏览0引用

Remission In Sle: Consensus Findings From A Large International Panel On Definitions Of Remission In Sle (Doris)

R. Van Vollenhoven, C. Aranow, G. Bertsias, E. Silva Dutra De Oliviera Bonfa, R. Cervera, N. Costedoat-Chalumeau, T. Doerner, F. Houssiau, K. Lerstrom, E. Morand, M. Mosca, S. Navarra,

CLINICAL AND EXPERIMENTAL RHEUMATOLOGYno. 3 (2015): S6-S6

引用0浏览0引用

THU0283 Two Year Follow-Up on Biologics Use in 13 Centers - Data from the International Registry for Biologics in SLE (IRBIS)

J G Hanley,Daniel J Wallace,Soren Jacobsen, M Mild,Michelle Petri,Sasha Bernatsky,S C Bae,Manuel Ramoscasals, F J Garciahernandez, M D M Ayalaguiterrez,R Van Vollenhoven,Rosalind Ramseygoldman,

Annals of the Rheumatic Diseases（2014）

引用0浏览0引用

AB0615 Favorable response to belimumab seen at three months

Katrina Shum,Jill P Buyon,Andrew G Franks,Richard A Furie,Diane L Kamen,Susan Manzi,Michelle Petri,Rosalind Ramseygoldman,C E Tseng,Daniel J Wallace,R Van Vollenhoven,Anca Askanase

Annals of the Rheumatic Diseases（2014）

引用23浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn